Features | Partner Sites | Information | LinkXpress
Sign In
SCHILLER AG
AMPRONIX
TERARECON, INC.

Cancer Therapy Efficacy May Be Determined Using MRI and Oxygen

By Medimaging International staff writers
Posted on 30 Jun 2009
Utilizing a simple magnetic resonance imaging (MRI) scan involving breathing oxygen might help oncologists determine the best treatment for some cancer patients, reported researchers.

Earlier studies have shown that the amount of oxygen present in a tumor can be a predictor of how well a patient will respond to treatment. Tumors with little oxygen tend to grow stronger and resist both radiotherapy and chemotherapy. Until now, however, the only way to measure the oxygen level in a tumor, and thus determine which treatment might be more effective, was to insert a huge needle directly into the cancerous tumor.

The new technique, known as blood oxygen level-dependent (BOLD) MRI, can detect oxygen levels in tumors without the need for an invasive procedure. The patient need only be able to breathe in oxygen when undergoing an MRI. "The patient simply inhales pure oxygen, which then circulates through the bloodstream, including to the tumors,” said Dr. Ralph Mason, professor of radiology at the University of Texas (UT) Southwestern Medical Center (Dallas, USA), director of the UT Southwestern Cancer Imaging Center, and senior author of a study appearing online in June 2009 in an issue of the journal Magnetic Resonance in Medicine (MRM). "Using MRI, we can then go in and estimate how much oxygen a particular tumor is taking up, providing us some insight into how the tumor is behaving and what sort of treatment might be effective.”

The most significant finding, according to Dr. Mason, is that BOLD MRI performed as well as the standard yet more invasive procedure for viewing tumors. That method, known as fluorocarbon relaxometry using echo planar imaging for dynamic oxygen mapping (FREDOM) MRI, requires the injection of a chemical called a reporter molecule directly into the tumor. "The BOLD technique appears to indicate accurately the oxygen levels in tumors,” Dr. Mason said. "Because BOLD is immediately applicable to patients, this holds promise as a new method for predicting response to therapy.”

BOLD MRI has been used extensively in studying brain function, but the procedure has only recently begun to be used to assess blood oxygenation and vascular function in tumors. Physicians at UT Southwestern are already evaluating BOLD MRI in patients with cervical, prostate, and head and neck cancer. They have proposed using it in lung cancer patients as well, reported Dr. Mason. Earlier research has shown that those specific tumor types are more likely to have little oxygen.

In the published study, researchers captured multiple images of breast tumors implanted just below the skin of rats, which were given anesthesia to help them remain still during the imaging process. Humans do not require anesthesia, according to Dr. Mason.

Dr. Mason reported that the team took the research back to the preclinical stage because they needed to better define what physicians were seeing in the clinic and whether the findings were reproducible. He reported that examining each form of cancer in this way presents its own technical challenges. For example, the motion of the lungs or the design of a facemask for breathing oxygen must be taken into account. "If we can prove that the test is meaningful in animals, then it is that much more worthwhile to argue for doing it in a patient. This preclinical work provides the foundation for future clinical studies,” Dr. Mason said. "It helps justify doing a larger clinical trial with the goal of ultimately becoming a diagnostic test for oncologists.”

Researchers currently are trying to determine how much oxygen must be inhaled by a patient in order to be effective. The next step is to expand studies in patients and validate the relevance to more tumor types.

Related Links:
University of Texas Southwestern Medical Center


RTI ELECTRONICS AB
SuperSonic Imagine
RADCAL

Channels

Ultrasound

view channel
Image: Siemens Healthcare has launched the HELX Evolution, the newest iteration of its Acuson S range of ultrasound imaging systems (Photo courtesy of Siemens Healthcare).

Ultrasound Imaging System Enhancements Include High Definition Transducers, Sophisticated Elastography, and Tissue Strain Analysis

New features designed for a range of ultrasound systems include enhanced image quality with a large 21.5-inch liquid crystal diode (LCD) monitor, high definition (HD) transducers, optimized contrast agent... Read more

Nuclear medicine

view channel
Image: Sagittal section of brain PET image at four hours after 64CuCl2 injection with disulfiram or D-penicillamine in MD model mice (Photo courtesy of the RIKEN Center for Life Science Technologies).

PET Imaging Used to Assess Effectiveness of Menkes Disease Treatments

Japanese scientists are using positron emission tomography (PET) imaging to visualize the distribution of copper in the body using lab mice. Copper distribution is deregulated in a genetic disorder called... Read more

General/Advanced Imaging

view channel

Secondary Light Emission Generated by Plasmonic Nanostructures May Improve Medical Imaging Technology

New clues into light emission at different wavelengths generated by elements known plasmonic nanostructures may help to improve medical imaging technology. A plasmon is a quantum of plasma oscillation. The plasmon is a quasiparticle resulting from the quantization of plasma oscillations just as photons, and phonons are... Read more

Imaging IT

view channel

Software Designed for the Assessment of Orthopedic Implant Fixation and Bone Segment Motion

Model-based roentgen stereophotogrammetric analysis (MBRSA) software has been developed for evaluation of orthopedic implant fixation and bone segment motion. The software is the first to measure the in vivo three-dimensional (3D) position and/or relative motion of metal implants, markers beads, and/or bone segments in... Read more

Industry News

view channel

Collaboration Expands Capacity for Proton Therapy Clinical Research and Patient Treatments

Varian Medical Systems (Palo Alto, CA, USA) and the Paul Scherrer Institute (PSI; Villigen PSI, Switzerland) are extending an existing collaboration in the field of proton therapy to offer patients more accurate cancer treatments using intensity-modulated proton therapy (IMPT). Under the agreement, Varian will also... Read more
 
Copyright © 2000-2014 Globetech Media. All rights reserved.